American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

BioCryst Pharmaceuticals Inc

BCRX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

BCRX historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of BCRX by members of U.S. Congress

Politician Type Traded
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jul 10, 2026
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Nov 13, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 Oct 16, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep 15, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Aug 11, 2022
BCRX Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
BCRX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BCRX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in BCRX holdings by institutional investors

Insider Trading

Quarterly net insider trading by BCRX's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $10,000 Oct 22, 2018 Issue: None
  • $20,000 Jul 20, 2018 Issue: None
  • $20,000 Jul 20, 2018 Issue: None
  • $20,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 22, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 22, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Apr 20, 2017 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Apr 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 23, 2017 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jan 23, 2017 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Oct 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Sep 26, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2016 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jul 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Apr 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Oct 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $40,000 Jul 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Apr 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Apr 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $40,000 Jan 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jan 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Oct 20, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Oct 20, 2014 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Jul 21, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jul 21, 2014 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $10,000 Apr 21, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $10,000 Apr 21, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $10,000 Apr 07, 2014 Issue: Medical/Disease Research/Clinical Labs Defense Health Issues Homeland Security
  • $40,000 Oct 21, 2013 Issue: Pharmacy Defense Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs Health Issues
  • $20,000 Oct 21, 2013 Issue: Medical/Disease Research/Clinical Labs Pharmacy Health Issues Disaster Planning/Emergencies Defense
  • $40,000 Jul 22, 2013 Issue: Health Issues Disaster Planning/Emergencies Pharmacy Medical/Disease Research/Clinical Labs Defense
  • $20,000 Jul 22, 2013 Issue: Medical/Disease Research/Clinical Labs Pharmacy Health Issues Disaster Planning/Emergencies Defense
  • $30,000 Jul 18, 2013 Issue: Homeland Security Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs Science/Technology Defense
  • $30,000 Oct 20, 2011 Issue: Health Issues
  • $20,000 Oct 17, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Jul 20, 2011 Issue: Health Issues
  • $30,000 Jul 20, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Apr 20, 2011 Issue: Health Issues
  • $30,000 Apr 12, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Jan 20, 2011 Issue: Health Issues
  • $30,000 Jan 18, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Jan 18, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Oct 20, 2010 Issue: Health Issues
  • $50,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Jul 20, 2010 Issue: Health Issues
  • $30,000 Jul 19, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jul 12, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Apr 20, 2010 Issue: Health Issues
  • $50,000 Apr 19, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Apr 12, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jan 20, 2010 Issue: Health Issues
  • $30,000 Jan 14, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jan 13, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Oct 13, 2009 Issue: Health Issues
  • $30,000 Oct 13, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jul 10, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Apr 16, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jan 13, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Oct 17, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Jul 16, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Apr 17, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Feb 05, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Aug 13, 2007 Issue: Homeland Security Economics/Economic Development
  • $40,000 Feb 13, 2007 Issue: Homeland Security
  • $40,000 Jul 27, 2006 Issue: Medical/Disease Research/Clinical Labs Homeland Security
  • $40,000 Feb 14, 2006 Issue: Medical/Disease Research/Clinical Labs Homeland Security
  • $40,000 Jul 29, 2005 Issue: Homeland Security Medical/Disease Research/Clinical Labs
Revolving Door

Former government officials who have lobbied for BCRX

Quiver Logo

No former government officials on record as having lobbied for BCRX

Revolving Door Dashboard
Corporate Lobbying

BCRX Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

BCRX Revenue by Segment or Geography

By Segment
By Geography
BCRX Income Statement
BCRX Balance Sheet
BCRX Cash Flow
U.S. Patents

New BCRX patent grants

  • Patent Title: Pyrrolopyrimidine amines as complement inhibitors Jul. 14, 2026
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Mar. 31, 2026
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Mar. 31, 2026
  • Patent Title: Plasma kallikrein inhibitors and methods of use thereof in ocular disorders Mar. 31, 2026
  • Patent Title: Oral complement factor d inhibitors Feb. 24, 2026
  • Patent Title: Synthesis of an antiviral azasugar triphosphate Feb. 17, 2026
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Feb. 17, 2026
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Feb. 10, 2026
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Feb. 10, 2026
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Feb. 10, 2026
  • Patent Title: Process-scale synthesis of a plasma kallikrein inhibitor Dec. 23, 2025
  • Patent Title: Pyrrolo 12.3-dipyrimidine compounds and analogues thereof Dec. 02, 2025
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Jul. 01, 2025
  • Patent Title: Human plasma kallikrein inhibitors Dec. 10, 2024
  • Patent Title: Antiviral treatments Oct. 22, 2024
  • Patent Title: Human plasma kallikrein inhibitors Oct. 15, 2024
  • Patent Title: Imidazole-containing inhibitors of alk2 kinase Aug. 06, 2024
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jul. 23, 2024
  • Patent Title: Methods and compositions for treatment of zika virus infection May. 07, 2024
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jan. 09, 2024
  • Patent Title: Human plasma kallikrein inhibitors Nov. 07, 2023
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jul. 25, 2023
  • Patent Title: Human plasma kallikrein inhibitors Jul. 25, 2023
  • Patent Title: Human plasma kallikrein inhibitors Jul. 25, 2023
  • Patent Title: Human plasma kallikrein inhibitors Jun. 27, 2023
  • Patent Title: Imidazole-containing inhibitors of alk2 kinase May. 30, 2023
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Apr. 04, 2023
  • Patent Title: Prodrugs of kallikrein inhibitors Apr. 04, 2023
  • Patent Title: Indole compounds and analogues thereof Jan. 24, 2023
  • Patent Title: Antiviral treatments Oct. 11, 2022
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jun. 28, 2022
  • Patent Title: Human plasma kallikrein inhibitors Jan. 25, 2022
  • Patent Title: Human plasma kallikrein inhibitors Dec. 21, 2021
  • Patent Title: Human plasma kallikrein inhibitors Dec. 07, 2021
  • Patent Title: Methods and compositions for inhibition of polymerase Nov. 16, 2021
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Sep. 14, 2021
  • Patent Title: Methods of treating hematologic cancers Sep. 07, 2021
  • Patent Title: Human plasma kallikrein inhibitors Jul. 20, 2021
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jun. 01, 2021
  • Patent Title: Antiviral treatments Sep. 26, 2017
  • Patent Title: Compositions and methods for inhibiting viral polymerase Feb. 28, 2017
  • Patent Title: Anti-influenza compositions and methods Nov. 22, 2016
  • Patent Title: Methods and compositions for inhibition of polymerase Nov. 15, 2016
  • Patent Title: Antiviral treatments Jul. 15, 2014
  • Patent Title: Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-d] pyrimidin-4-one Aug. 06, 2013
  • Patent Title: Antiviral nucleoside analogs May. 14, 2013
  • Patent Title: Tetrahydrofuro [3,4-d] dioxolane compounds for use in the treatment of viral infections and cancer Aug. 14, 2012
  • Patent Title: Hepatitis c therapies Apr. 24, 2012
  • Patent Title: Therapeutic furopyrimidines and thienopyrimidines Mar. 13, 2012
  • Patent Title: Antiviral therapeutic agents Aug. 09, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to BCRX from public contracts

BCRX News

Recent insights relating to BCRX

CNBC Recommendations

Recent picks made for BCRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BCRX

BCRX Analyst Ratings

BCRX Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
BCRX Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $BCRX stock a Buy, Sell, or Hold?

  • What is the price target for $BCRX stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

BCRX Top Shareholders
Shareholder
Shares Held
BCRX Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $BCRX stock?

  • Who owns the most shares of $BCRX stock?

  • What funds own $BCRX stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BCRX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BCRX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About BCRX

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

  • Address Durham, NC
  • Market Cap 2.2 billion
  • Employees 435
  • Industrial Classification Biological Products, (No Diagnostic Substances)

BioCryst Pharmaceuticals Inc (BCRX) Historical Stock Prices

BioCryst Pharmaceuticals Inc (BCRX) closed at $8.57 on September 23, 2026. Over the past year its adjusted close ranged from $6.24 to $11.11. Daily prices go back to January 2, 2014, 3,200 trading days in all.

  • 1 month-11.47%
  • 3 months-14.30%
  • Year to date+9.87%
  • 1 year+9.59%
  • 3 years+16.60%
  • 5 years-42.56%
  • Max+8.48%
See every congressional and insider trade on the BCRX price chart

Quiver Premium charts BCRX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 8.75 8.86 8.46 8.57 8.57 4,466,765
Sep 22, 2026 8.87 9.04 8.72 8.78 8.78 3,442,408
Sep 21, 2026 8.75 8.85 8.57 8.76 8.76 3,462,946
Sep 18, 2026 8.60 8.84 8.49 8.68 8.68 12,746,888
Sep 17, 2026 8.54 8.73 8.43 8.70 8.70 5,220,505
Sep 16, 2026 8.15 8.45 8.11 8.43 8.43 5,860,006
Sep 15, 2026 8.19 8.23 8.02 8.16 8.16 6,113,064
Sep 14, 2026 8.17 8.38 8.10 8.23 8.23 5,096,672
Sep 11, 2026 8.30 8.40 8.11 8.12 8.12 3,591,765
Sep 10, 2026 8.34 8.46 8.04 8.29 8.29 9,001,379
Sep 9, 2026 9.07 9.23 8.80 8.80 8.80 5,152,521
Sep 8, 2026 9.12 9.40 8.96 9.06 9.06 9,687,920
Sep 4, 2026 10.00 10.10 9.89 9.96 9.96 1,495,739
Sep 3, 2026 10.15 10.22 9.94 10.09 10.09 1,973,960
Sep 2, 2026 10.00 10.23 9.83 10.17 10.17 3,130,174
Sep 1, 2026 9.72 9.96 9.63 9.92 9.92 3,367,135
Aug 31, 2026 9.72 9.72 9.46 9.70 9.70 2,756,280
Aug 28, 2026 9.82 9.96 9.72 9.82 9.82 2,702,947
Aug 27, 2026 9.75 9.92 9.55 9.87 9.87 2,479,399
Aug 26, 2026 9.77 9.90 9.71 9.83 9.83 1,858,895
Aug 25, 2026 9.79 9.92 9.70 9.83 9.83 2,332,655
Aug 24, 2026 9.50 9.76 9.48 9.68 9.68 2,010,324
Aug 21, 2026 9.72 9.90 9.48 9.55 9.55 2,496,708
Aug 20, 2026 9.92 9.99 9.60 9.66 9.66 2,329,247
Aug 19, 2026 9.93 10.11 9.77 10.07 10.07 2,906,761
Aug 18, 2026 9.89 9.94 9.54 9.70 9.70 2,122,109
Aug 17, 2026 9.72 10.03 9.65 9.94 9.94 2,122,652
Aug 14, 2026 9.68 9.80 9.46 9.74 9.74 3,820,778
Aug 13, 2026 10.59 10.63 9.70 9.81 9.81 4,583,163
Aug 12, 2026 10.33 10.68 10.10 10.59 10.59 3,865,676
Aug 11, 2026 9.86 10.59 9.78 10.34 10.34 5,034,052
Aug 10, 2026 9.33 9.86 9.28 9.84 9.84 4,017,077
Aug 7, 2026 9.50 9.66 9.23 9.38 9.38 4,383,646
Aug 6, 2026 9.04 9.53 8.98 9.30 9.30 4,044,212
Aug 5, 2026 9.44 9.67 8.80 9.07 9.07 6,093,801
Aug 4, 2026 8.82 9.04 8.76 9.02 9.02 2,920,912
Aug 3, 2026 9.00 9.07 8.77 8.81 8.81 3,190,272
Jul 31, 2026 9.17 9.25 8.93 8.98 8.98 2,929,185
Jul 30, 2026 9.44 9.50 9.15 9.24 9.24 2,323,022
Jul 29, 2026 9.66 9.79 9.51 9.53 9.53 2,194,894
Jul 28, 2026 9.64 9.79 9.51 9.74 9.74 2,875,375
Jul 27, 2026 9.64 9.91 9.58 9.58 9.58 4,310,711
Jul 24, 2026 9.41 9.48 9.29 9.34 9.34 1,851,888
Jul 23, 2026 9.32 9.48 9.25 9.38 9.38 1,635,328
Jul 22, 2026 9.37 9.69 9.36 9.51 9.51 2,550,092
Jul 21, 2026 9.18 9.43 9.11 9.42 9.42 2,291,421
Jul 20, 2026 9.38 9.47 9.11 9.11 9.11 2,383,783
Jul 17, 2026 8.99 9.32 8.95 9.29 9.29 3,272,762
Jul 16, 2026 9.35 9.44 9.09 9.11 9.11 3,561,547
Jul 15, 2026 9.78 9.91 9.17 9.41 9.41 6,813,775
Jul 14, 2026 9.91 9.98 9.62 9.74 9.74 3,968,215
Jul 13, 2026 10.13 10.23 9.80 9.91 9.91 3,147,935
Jul 10, 2026 10.69 10.72 10.28 10.45 10.45 3,359,350
Jul 9, 2026 11.15 11.22 10.69 10.72 10.72 3,982,332
Jul 8, 2026 10.95 11.19 10.51 11.11 11.11 7,429,410
Jul 7, 2026 10.34 11.03 10.00 10.99 10.99 10,280,196
Jul 6, 2026 9.80 10.25 9.71 10.17 10.17 4,380,034
Jul 2, 2026 9.74 9.85 9.52 9.84 9.84 4,860,048
Jul 1, 2026 10.15 10.15 9.59 9.65 9.65 4,866,525
Jun 30, 2026 9.81 10.17 9.68 10.00 10.00 7,719,752
Jun 29, 2026 9.89 10.04 9.47 9.55 9.55 6,533,643
Jun 26, 2026 9.91 10.19 9.66 9.94 9.94 10,986,513
Jun 25, 2026 10.00 10.94 9.70 9.90 9.90 19,059,610
Jun 24, 2026 9.42 10.01 9.39 10.00 10.00 8,519,801
Jun 23, 2026 9.18 9.50 9.10 9.31 9.31 5,144,624
Jun 22, 2026 9.04 9.34 8.91 9.14 9.14 7,405,439
Jun 18, 2026 9.10 9.54 8.98 8.99 8.99 8,882,726
Jun 17, 2026 8.95 9.18 8.82 8.95 8.95 4,450,756
Jun 16, 2026 9.09 9.18 8.79 8.92 8.92 3,575,476
Jun 15, 2026 8.76 9.08 8.71 9.06 9.06 4,153,927
Jun 12, 2026 8.47 8.73 8.45 8.70 8.70 2,394,656
Jun 11, 2026 8.21 8.63 8.10 8.50 8.50 3,820,257
Jun 10, 2026 8.31 8.40 8.15 8.19 8.19 3,652,264
Jun 9, 2026 8.52 8.63 8.32 8.33 8.33 3,797,993
Jun 8, 2026 8.43 8.47 8.24 8.43 8.43 4,085,998
Jun 5, 2026 8.50 8.60 8.33 8.41 8.41 2,500,853
Jun 4, 2026 8.38 8.51 8.31 8.47 8.47 3,465,371
Jun 3, 2026 8.33 8.47 8.06 8.25 8.25 4,229,800
Jun 2, 2026 8.42 8.45 8.24 8.34 8.34 4,510,976
Jun 1, 2026 8.76 8.85 8.53 8.57 8.57 3,084,265
May 29, 2026 9.05 9.10 8.82 8.91 8.91 3,232,346
May 28, 2026 9.09 9.15 8.91 9.10 9.10 3,349,922
May 27, 2026 8.48 9.23 8.44 9.12 9.12 6,575,054
May 26, 2026 8.19 8.53 8.11 8.47 8.47 4,013,240
May 22, 2026 8.35 8.54 8.21 8.29 8.29 4,165,156
May 21, 2026 8.69 8.69 8.36 8.37 8.37 4,051,694
May 20, 2026 8.78 8.97 8.72 8.74 8.74 2,575,025
May 19, 2026 8.97 9.01 8.73 8.77 8.77 3,876,459
May 18, 2026 9.03 9.07 8.76 8.97 8.97 3,797,371
May 15, 2026 9.56 9.59 9.00 9.02 9.02 4,576,465
May 14, 2026 9.77 9.82 9.48 9.57 9.57 5,326,914
May 13, 2026 8.68 9.79 8.65 9.60 9.60 18,948,874
May 12, 2026 8.64 8.84 8.59 8.80 8.80 3,320,003
May 11, 2026 8.67 8.80 8.52 8.58 8.58 3,710,142
May 8, 2026 8.96 8.99 8.55 8.62 8.62 6,164,545
May 7, 2026 8.80 8.94 8.56 8.90 8.90 5,549,204
May 6, 2026 8.63 8.91 7.79 8.83 8.83 9,013,159
May 5, 2026 9.22 9.30 8.94 9.03 9.03 3,745,178
May 4, 2026 9.16 9.39 9.02 9.20 9.20 3,454,101
May 1, 2026 9.16 9.33 9.09 9.19 9.19 2,307,142
Apr 30, 2026 9.01 9.37 8.96 9.16 9.16 3,321,404
Apr 29, 2026 9.02 9.19 8.81 8.99 8.99 3,313,667
Apr 28, 2026 9.04 9.15 8.80 8.86 8.86 2,556,707
Apr 27, 2026 8.88 9.20 8.88 8.90 8.90 3,087,176
Apr 24, 2026 8.73 8.95 8.62 8.94 8.94 2,623,776
Apr 23, 2026 9.03 9.12 8.70 8.76 8.76 2,465,029
Apr 22, 2026 8.58 9.02 8.58 9.01 9.01 3,725,915
Apr 21, 2026 9.20 9.27 8.56 8.58 8.58 5,079,142
Apr 20, 2026 9.40 9.45 9.09 9.19 9.19 3,204,429
Apr 17, 2026 9.63 9.67 9.43 9.50 9.50 3,656,729
Apr 16, 2026 9.45 9.57 9.32 9.52 9.52 4,319,862
Apr 15, 2026 9.75 9.77 9.38 9.44 9.44 4,842,303
Apr 14, 2026 9.39 9.68 9.37 9.67 9.67 3,711,946
Apr 13, 2026 9.51 9.56 9.34 9.41 9.41 3,194,868
Apr 10, 2026 9.89 9.90 9.49 9.56 9.56 4,432,204
Apr 9, 2026 9.71 9.98 9.71 9.89 9.89 4,608,553
Apr 8, 2026 9.65 9.92 9.64 9.78 9.78 8,649,238
Apr 7, 2026 9.42 9.62 9.15 9.59 9.59 2,923,886
Apr 6, 2026 8.98 9.68 8.95 9.47 9.47 3,462,193
Apr 2, 2026 9.31 9.35 8.92 9.02 9.02 7,824,922
Apr 1, 2026 9.54 9.66 9.27 9.38 9.38 4,907,272
Mar 31, 2026 9.57 9.69 9.30 9.52 9.52 5,655,326
Mar 30, 2026 9.28 9.52 9.17 9.45 9.45 2,987,244
Mar 27, 2026 9.59 9.73 9.33 9.33 9.33 4,324,862
Mar 26, 2026 9.19 9.69 8.89 9.56 9.56 6,618,203
Mar 25, 2026 9.90 10.11 9.24 9.40 9.40 7,736,817
Mar 24, 2026 10.13 10.13 9.42 9.66 9.66 11,145,790
Mar 23, 2026 9.82 10.04 9.63 9.80 9.80 9,242,068
Mar 20, 2026 9.73 10.32 9.64 9.70 9.70 13,148,754
Mar 19, 2026 9.15 9.97 9.05 9.81 9.81 9,235,428
Mar 18, 2026 9.18 9.19 8.91 9.16 9.16 4,629,012
Mar 17, 2026 9.30 9.57 8.95 9.21 9.21 6,012,786
Mar 16, 2026 8.22 9.60 8.20 9.30 9.30 19,874,868
Mar 13, 2026 8.45 8.54 8.15 8.22 8.22 5,516,666
Mar 12, 2026 8.49 8.58 8.34 8.38 8.38 4,257,026
Mar 11, 2026 8.69 8.79 8.39 8.49 8.49 3,055,694
Mar 10, 2026 8.63 8.90 8.63 8.75 8.75 4,005,515
Mar 9, 2026 8.48 8.66 8.39 8.62 8.62 5,427,736
Mar 6, 2026 8.40 8.51 8.31 8.48 8.48 3,473,695
Mar 5, 2026 8.48 8.64 8.40 8.50 8.50 7,788,771
Mar 4, 2026 8.66 8.72 8.38 8.57 8.57 4,911,559
Mar 3, 2026 8.51 8.86 8.45 8.69 8.69 5,185,686
Mar 2, 2026 8.65 8.86 8.53 8.63 8.63 5,919,839
Feb 27, 2026 7.95 8.83 7.91 8.75 8.75 14,875,627
Feb 26, 2026 8.20 8.20 7.59 7.90 7.90 8,077,110
Feb 25, 2026 7.67 7.69 7.46 7.55 7.55 3,373,109
Feb 24, 2026 7.64 7.70 7.56 7.61 7.61 1,951,631
Feb 23, 2026 7.45 7.61 7.42 7.58 7.58 2,637,166
Feb 20, 2026 7.47 7.50 7.31 7.45 7.45 2,602,786
Feb 19, 2026 7.26 7.48 7.16 7.48 7.48 2,638,166
Feb 18, 2026 6.97 7.36 6.97 7.26 7.26 4,676,431
Feb 17, 2026 6.78 7.00 6.76 6.95 6.95 3,798,774
Feb 13, 2026 6.87 6.91 6.72 6.76 6.76 4,508,025
Feb 12, 2026 6.82 6.86 6.61 6.80 6.80 2,024,584
Feb 11, 2026 6.53 6.91 6.46 6.84 6.84 3,725,293
Feb 10, 2026 6.31 6.64 6.30 6.55 6.55 5,287,681
Feb 9, 2026 6.34 6.38 6.26 6.30 6.30 1,762,904
Feb 6, 2026 6.43 6.43 6.26 6.38 6.38 6,346,434
Feb 5, 2026 6.44 6.57 6.23 6.24 6.24 4,516,613
Feb 4, 2026 6.72 6.76 6.40 6.42 6.42 4,420,550
Feb 3, 2026 6.61 6.75 6.55 6.70 6.70 4,135,591
Feb 2, 2026 6.55 6.75 6.46 6.63 6.63 3,721,998
Jan 30, 2026 6.61 6.75 6.42 6.58 6.58 3,294,792
Jan 29, 2026 6.66 6.79 6.60 6.67 6.67 3,638,279
Jan 28, 2026 6.76 6.83 6.61 6.66 6.66 2,710,602
Jan 27, 2026 6.81 6.94 6.59 6.76 6.76 4,709,533
Jan 26, 2026 6.79 7.07 6.72 6.86 6.86 5,504,340
Jan 23, 2026 6.72 7.15 6.70 6.79 6.79 4,811,164
Jan 22, 2026 6.69 6.87 6.63 6.75 6.75 6,694,342
Jan 21, 2026 6.66 6.74 6.60 6.72 6.72 3,307,537
Jan 20, 2026 6.50 6.70 6.46 6.67 6.67 5,417,200
Jan 16, 2026 7.12 7.17 6.58 6.66 6.66 6,759,084
Jan 15, 2026 6.79 7.27 6.63 7.17 7.17 7,488,826
Jan 14, 2026 6.72 6.85 6.69 6.78 6.78 4,662,470
Jan 13, 2026 7.13 7.13 6.69 6.75 6.75 6,441,502
Jan 12, 2026 7.30 7.33 6.99 7.09 7.09 7,805,732
Jan 9, 2026 7.65 8.04 7.38 7.40 7.40 6,056,456
Jan 8, 2026 7.85 7.91 7.51 7.62 7.62 3,692,736
Jan 7, 2026 7.59 8.05 7.56 7.92 7.92 3,901,943
Jan 6, 2026 7.38 7.63 7.36 7.58 7.58 4,981,772
Jan 5, 2026 7.41 7.53 7.21 7.41 7.41 4,411,957
Jan 2, 2026 7.82 7.90 7.46 7.50 7.50 2,818,727
Dec 31, 2025 7.67 7.83 7.64 7.80 7.80 2,940,744
Dec 30, 2025 7.65 7.68 7.54 7.66 7.66 3,136,024
Dec 29, 2025 7.61 7.76 7.52 7.71 7.71 2,297,042
Dec 26, 2025 7.69 7.69 7.53 7.63 7.63 1,625,793
Dec 24, 2025 7.48 7.76 7.47 7.70 7.70 1,457,534
Dec 23, 2025 7.59 7.64 7.44 7.53 7.53 2,139,573
Dec 22, 2025 7.40 7.69 7.35 7.61 7.61 3,554,989
Dec 19, 2025 7.24 7.55 7.19 7.41 7.41 6,236,002
Dec 18, 2025 7.19 7.38 7.12 7.29 7.29 3,743,010
Dec 17, 2025 7.43 7.58 7.11 7.13 7.13 4,699,241
Dec 16, 2025 7.61 7.70 7.36 7.47 7.47 3,246,139
Dec 15, 2025 7.63 7.92 7.43 7.59 7.59 4,954,269
Dec 12, 2025 7.82 7.82 7.23 7.57 7.57 5,223,129
Dec 11, 2025 7.68 7.77 7.54 7.58 7.58 2,657,266
Dec 10, 2025 7.62 7.69 7.51 7.66 7.66 2,734,990
Dec 9, 2025 7.70 7.85 7.63 7.64 7.64 3,220,568
Dec 8, 2025 7.71 7.98 7.66 7.70 7.70 3,817,340
Dec 5, 2025 7.83 7.93 7.45 7.59 7.59 3,199,536
Dec 4, 2025 7.85 8.17 7.79 7.83 7.83 6,724,910
Dec 3, 2025 7.11 7.88 7.11 7.85 7.85 7,604,083
Dec 2, 2025 7.17 7.30 7.12 7.16 7.16 3,570,663
Dec 1, 2025 7.08 7.20 7.01 7.13 7.13 3,200,298
Nov 28, 2025 7.14 7.22 7.05 7.18 7.18 1,484,759
Nov 26, 2025 6.85 7.14 6.81 7.10 7.10 3,731,150
Nov 25, 2025 6.91 7.01 6.71 6.85 6.85 5,243,955
Nov 24, 2025 7.00 7.05 6.71 6.83 6.83 4,942,440
Nov 21, 2025 7.03 7.17 6.95 6.97 6.97 3,906,833
Nov 20, 2025 7.04 7.09 6.89 7.03 7.03 3,573,164
Nov 19, 2025 7.01 7.07 6.73 6.93 6.93 3,234,698
Nov 18, 2025 7.00 7.12 6.97 7.00 7.00 2,466,034
Nov 17, 2025 7.10 7.21 7.00 7.03 7.03 3,261,484
Nov 14, 2025 6.88 7.18 6.85 7.08 7.08 3,680,208
Nov 13, 2025 7.14 7.23 6.90 6.90 6.90 4,832,495
Nov 12, 2025 7.22 7.32 7.14 7.18 7.18 3,442,515
Nov 11, 2025 7.17 7.33 7.11 7.23 7.23 3,663,807
Nov 10, 2025 7.15 7.27 7.08 7.20 7.20 3,779,246
Nov 7, 2025 7.03 7.12 6.84 7.09 7.09 5,770,379
Nov 6, 2025 7.14 7.15 6.87 7.03 7.03 4,967,751
Nov 5, 2025 6.86 7.22 6.80 7.17 7.17 5,786,477
Nov 4, 2025 6.70 6.89 6.51 6.76 6.76 8,818,662
Nov 3, 2025 7.15 7.26 6.75 6.86 6.86 9,821,632
Oct 31, 2025 7.28 7.47 7.18 7.32 7.32 5,729,086
Oct 30, 2025 7.31 7.43 7.21 7.25 7.25 4,881,327
Oct 29, 2025 7.18 7.38 7.17 7.31 7.31 5,075,703
Oct 28, 2025 7.31 7.33 7.17 7.24 7.24 6,040,964
Oct 27, 2025 7.26 7.34 7.17 7.31 7.31 4,220,290
Oct 24, 2025 7.23 7.34 7.15 7.20 7.20 3,902,131
Oct 23, 2025 7.05 7.24 6.97 7.19 7.19 3,805,727
Oct 22, 2025 6.99 7.16 6.87 7.08 7.08 6,210,797
Oct 21, 2025 6.87 6.99 6.75 6.99 6.99 3,263,367
Oct 20, 2025 6.67 6.93 6.59 6.93 6.93 6,473,967
Oct 17, 2025 6.67 6.68 6.44 6.63 6.63 7,575,952
Oct 16, 2025 6.87 6.92 6.70 6.72 6.72 10,483,788
Oct 15, 2025 6.53 6.88 6.46 6.81 6.81 15,805,240
Oct 14, 2025 6.62 6.98 6.00 6.42 6.42 36,939,725
Oct 13, 2025 7.23 7.26 6.96 7.04 7.04 3,355,933
Oct 10, 2025 7.25 7.32 7.08 7.22 7.22 3,292,233
Oct 9, 2025 7.24 7.33 7.22 7.25 7.25 4,089,202
Oct 8, 2025 7.06 7.32 6.95 7.28 7.28 5,783,063
Oct 7, 2025 7.00 7.07 6.93 6.95 6.95 3,957,161
Oct 6, 2025 7.14 7.14 7.00 7.02 7.02 4,118,249
Oct 3, 2025 7.40 7.46 7.14 7.15 7.15 3,691,959
Oct 2, 2025 7.36 7.42 7.26 7.33 7.33 2,809,263
Oct 1, 2025 7.49 7.52 7.24 7.37 7.37 5,323,060
Sep 30, 2025 7.58 7.62 7.42 7.59 7.59 2,273,370
Sep 29, 2025 7.63 7.63 7.50 7.55 7.55 1,929,883
Sep 26, 2025 7.68 7.73 7.50 7.63 7.63 2,620,551
Sep 25, 2025 7.78 7.89 7.61 7.65 7.65 1,987,579
Sep 24, 2025 7.78 7.88 7.74 7.77 7.77 2,578,896
Sep 23, 2025 7.86 7.93 7.78 7.82 7.82 1,843,775

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
BioCryst Pharmaceuticals Inc Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at BCRX, per a recent SEC DEF 14A filing. We estimate that the median employee at BIOCRYST PHARMACEUTICALS INC is paid $274,492.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation